Build It Live at the HITLAB World Cup.
The DSMB review was conducted as part of the pre-planned clinical safety oversight process agreed upon with the U.S. FDA.
New 75,000-square-foot facility to open in October 2026 near Salt Lake City International Airport, extending company’s national reach for medical device manufacturers
The company’s comprehensive viral target atlas is designed to move development from reactive crisis response toward proactive, pre-identified genomic vulnerability mapping
New PATHOMIQ AI integration helps clinicians tailor active surveillance with greater confidence
Joint development strategy has been developed to address international deployment requirements if current outbreak continues or expands globally
Mosman to lead NanoKar’s next phase of translational validation, partner readiness, and strategic collaboration for its ITAM optimization platform
Recognition places Lumea among elite global winners including Medtronic and Thermo Fisher Scientific in one of digital health’s most competitive annual programs
Recent pathogens illustrate need for improved situational awareness capabilities, such as those provided by the Co-Dx PCR point-of-care platform
Funds will fuel sales team expansion and broader market access, advancing the company’s leadership in Implantable Tibial Neuromodulation (ITNM) for the treatment of urgency urinary incontinence (UUI)
351-patient trial completion marks a key milestone for the Celeste® program; topline data to be presented May 26 in Phoenix
FDA stated that the “proposed data may be capable of supporting the submission and review of an [NDA] under the accelerated approval pathway” for CNM-Au8 based on neurofilament light (NfL) biomarker data